« Back to Record
Citation APA

Snoeck, R., Andrei, G., Bodaghi, B., Lagneaux, L., Daelemans, D., de Clercq, E., Neyts, J., Schols, D., Naesens, L., Michelson, S., Bron, D., Otto, M. J., Bousseau, A., Nemecek, C., & Roy, C. (2002). 2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral research, 55(3), 413-424. doi:10.1016/S0166-3542(02)00074-8


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/89851

Snoeck, R., Andrei, G., Bodaghi, B., Lagneaux, L., Daelemans, D., de Clercq, E., Neyts, J., Schols, D., Naesens, L., Michelson, S., Bron, D., Otto, M. J., Bousseau, A., Nemecek, C., & Roy, C. (2002). 2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral research, 55(3), 413-424. doi:10.1016/S0166-3542(02)00074-8